SCHEMBL1179385

SCHEMBL1179385

CCCc1cc(-c2nc(-c3cc(C)nc(C)c3)no2)nc(NC)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 10/20 0.39
S1PR3 Q99500 6/20 0.39
NPC1 O15118 4/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ATM Q13315 1/20 0.33
HDAC4 P56524 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
RAB9A P51151 3/20 0.32
ALDH1A1 P00352 2/20 0.32
TP53 P04637 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NFKB1 P19838 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HTT P42858 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
ADORA2B P29275 1/20 0.31
NR1I2 O75469 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1178939 0.82 S1PR1 (0.37) S1PR1S1PR3NPC1MAPTKDM4E
SCHEMBL1179384 0.81 S1PR1 (0.38) S1PR1S1PR3NPC1MAPTKDM4E
SCHEMBL1179247 0.81 KDM4E (0.46) S1PR1S1PR3NPC1MAPTKDM4E
SCHEMBL1179245 0.80 S1PR1 (0.37) S1PR1S1PR3NPC1MAPTKDM4E
SCHEMBL1424742 0.80 S1PR1 (0.50) S1PR1S1PR3NPC1MAPTKDM4E
SCHEMBL1179883 0.79 KDM4E (0.43) S1PR1S1PR3NPC1MAPTKDM4E
SCHEMBL1179721 0.78 S1PR1 (0.38) S1PR1S1PR3
SCHEMBL1178755 0.77 KDM4E (0.55) NPC1MAPTKDM4EATMHTT
SCHEMBL1179431 0.76 ESR1 (0.49) S1PR1S1PR3NPC1KDM4EATM
SCHEMBL1424912 0.75 S1PR1 (0.51) S1PR1S1PR3NPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US claimed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP claimed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO claimed
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US disclosed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP disclosed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES TYMP, DPYD, ENTPD5 S1PR1 766/4885S1PR3 709/4885NPC1 3223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.